Shots:
- BioCryst Pharmaceuticals has entered into a definitive agreement to acquire Astria Therapeutics, strengthening its allergic & immunology portfolio
- As per the deal, Astria shareholders will receive $8.55 in cash + 0.59 BioCryst shares, valuing Astria at $13/share with an enterprise value of ~$700M (equity value: ~$920M), plus Astria shareholders will hold ~15% of pro forma equity in the combined company; closing expected in Q1’26
- Acquisition will add Navenibart, a P-III (ALPHA-ORBIT) trial asset with topline data expected in early 2027 for HAE, & Astria’s early-stage atopic dermatitis program STAR-0310, for which BioCryst plans to explore strategic alternatives
Ref: BioCryst | Image: Astria| Press Release
Related News:- BioCryst Reports the US FDA’s NDA Acceptance and Priority Review of Orladeyo for Hereditary Angioedema (HAE)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
